📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. (2014)

First Author: Backen A
Attributed to:  Infrastructure for collaboration: Leeds MRC Medical Bioinformatics Centre funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1158/1078-0432.ccr-13-3248

PubMed Identifier: 24947924

Publication URI: http://europepmc.org/abstract/MED/24947924

Type: Journal Article/Review

Volume: 20

Parent Publication: Clinical cancer research : an official journal of the American Association for Cancer Research

Issue: 17

ISSN: 1078-0432